Lyka Labs Ltd
Lyka Labs Q2 Results 2026 (FY27) statement: Revenue & Margins
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Lyka Labs Ltd Q2 FY27 key numbers
- Revenue
- Revenue from Operations for quarter ended 30th September 2026: Rs. 8,650.89 lakhs (Standalone), Rs. 8,650.89 lakhs (Consolidated).
As stated in Lyka Labs Ltd's Q2 FY27 results statement · published 30 Oct 2026. Reported figures, not investment advice.
Based on Lyka Labs Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Revenue from Operations for quarter ended 30th September 2026: Rs. EBITDA for the quarter ended 30th September 2026: ₹1,391 lakh, down 15% year-on-year (YoY) from ₹1,635 lakh.
From Lyka Labs Ltd's Q2 FY27 earnings-call transcript · updated 30 Oct 2026.
Revenue & Sales Performance
- Revenue from Operations for quarter ended 30th September 2026: Rs. 8,650.89 lakhs (Standalone), Rs. 8,650.89 lakhs (Consolidated).
- For same quarter ended 30th September 2025, Revenue from Operations was Rs. 4,230.94 lakhs (Standalone), Rs. 4,230.94 lakhs (Consolidated).
- Year-on-Year revenue growth for the quarter: approximately 104.5% increase (8,650.89 vs 4,230.94 lakhs).
Profitability & Margins
See what Lyka Labs Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
See what Lyka Labs Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Lyka Labs Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Lyka Labs Ltd said on order book & pipeline — free account, 30 seconds.
Lyka Labs Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹42 Cr, net profit ₹2 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
Others in Pharmaceuticals & Biotechnology this season
- Sigachi Industries Ltd (Q2 FY27)
Year-on-Year (YoY) Revenue Growth: 18.09% (Q2 FY27 vs Q2 FY26) . Key investor presentation takeaways from Sigachi Industries Ltd's Q2 FY27 investor presentation
- Advanced Enzyme Technologies Ltd (Q2 FY27)
Q2 FY27 revenue from operations: ₹2,145 million, up 16% YoY from ₹1,845 million in Q2 FY26 (Page 13, 5). Key investor presentation takeaways from Advanced Enzym
- IOL Chemicals (Q2 FY27)
Q2 FY27 revenue from operations: ₹795.0 Cr, a 40.1% year-on-year (YoY) increase from ₹567.5 Cr in Q2 FY26 (Page 7). Key investor presentation takeaways from IOL
- Anuh Pharma Ltd (Q2 FY27)
64.13 lakhs (~0.34% decline). Key results statement takeaways from Anuh Pharma Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Lyka Labs Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Lyka Labs Ltd Q2 FY27 results?
Revenue from Operations for quarter ended 30th September 2026: Rs. EBITDA for the quarter ended 30th September 2026: ₹1,391 lakh, down 15% year-on-year (YoY) from ₹1,635 lakh.
What is Lyka Labs Ltd share price analysis?
Lyka Labs Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹277 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Lyka Labs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.